JasonLGagliaMD
Endocrinology • Boston, MADiabetes, Lipid Metabolism, Parathyroid, Thyroid
Assistant Professor, Joslin Diabetes Center
Dr. Gaglia is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Joslin Pl
Room 470
Boston, MA 02215Phone+1 617-732-2675Fax+1 617-732-2452
Education & Training
Beth Israel Deaconess Medical CenterFellowship, Endocrinology, Diabetes, and Metabolism, 2003 - 2006- Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2001 - 2003
Harvard Medical SchoolClass of 2001
Certifications & Licensure
FL State Medical License 2021 - Present
MA State Medical License 2006 - 2025- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2011-2012
- Diabetes Recognition Program National Committee for Quality Assurance, 2010-2013
Clinical Trials
- Imaging of Type 1 Diabetes Progression Start of enrollment: 2012 Jan 01
- Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus Start of enrollment: 2014 Jan 01
- Gluten Immunity and Islet Autoimmunity in Type-1 Diabetes Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- 13 citationsExenatide extended release in patients with type 1 diabetes with and without residual insulin productionKevan C. Herold, Jesse Reynolds, James Dziura, David A. Baidal, Jason L. Gaglia
Diabetes, Obesity & Metabolism. 2020-11-01 - 26 citationsThe demise of islet allotransplantation in the United States: A call for an urgent regulatory update.Piotr Witkowski, Louis H. Philipson, Dixon B. Kaufman, Lloyd E. Ratner, Marwan S Abouljoud
American Journal of Transplantation. 2021-04-01 - 1274 citationsTh1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune diseaseLaurent Monney, Catherine A. Sabatos, Jason L. Gaglia, Akemi Ryu, Hanspeter Waldner
Nature. 2002-01-31
Press Mentions
Novo Nordisk Aims to Break Mould with New Pill for DiabetesFebruary 21st, 2018
Eli Lilly's Diabetes Pill Takes Market Share from J&J;, AstraJanuary 5th, 2016- Unease Grows Among U.S. Doctors over Indian Drug QualityMarch 18th, 2014
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
